Lakefront Biotherapeutics (LKFT) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $2.24B
- As of Nov 13, 2026
- P/E
- 6.18x
- Latest fiscal year
- P/B
- 0.61x
- Latest reported equity
- P/S
- 1.78x
- Latest fiscal year
- ROE
- 9.9%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $2.24B
- As of Nov 13, 2026
- P/E
- 6.18x
- Latest fiscal year
- P/B
- 0.61x
- Latest reported equity
- P/S
- 1.78x
- Latest fiscal year
- ROE
- 9.9%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
6.18x
P/B
0.61x
P/S
1.78x
Earnings and dividend metrics▾
Earnings
EPS
$5.50
Earnings per share
BPS
$55.42
Book value per share
ROE
9.9%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $5.50 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $55.42 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 9.9%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsApr–Jun 2021(FY2021 Q2)
No later quarterly filing was found for this company, so this shows the most recent quarter on record.
Revenue increased 39.8% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $118M+39.8%
—
FY19 Q2
$118M
Apr–Jun '20
$165M
Apr–Jun '21
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Apr–Jun 2021 are from the 6-K submitted to SEC EDGAR on Aug 5, 2021.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 39.8% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Aug 5, 2021 · 6-K · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Lakefront Biotherapeutics (LKFT) stock information
NASDAQ
Lakefront Biotherapeutics (LKFT) is listed on NASDAQ. Its market capitalization is about $2.2B. On trailing-twelve-month earnings the P/E ratio is 6.18, and the P/B ratio is 0.61. Return on equity is 9.9%. These figures are computed in-house from official filings and are reference information only.
Lakefront Biotherapeutics — frequently asked questions
- What is the P/E ratio of Lakefront Biotherapeutics (LKFT)?
- On a trailing-twelve-month basis, LKFT trades at a P/E ratio of 6.18. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Lakefront Biotherapeutics?
- LKFT has a market capitalization of about $2.2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.